Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION study

The most prevalent adverse event was diarrhoea in the SQV cohort (11%) and hypertrigliceridaemia in the FPV cohort (4%). Only four patients (2%) withdrew their treatment due to an adverse event. One patient (0.5%) with baseline mild renal impairment (GFR: 63 mL/min) withdrew his treatment due to a grade 1 GFR decrease. Conclusion In this cohort, concomitant use of TDF with SQV or FPV was associated with good tolerability and an adequate rate of viral effectiveness, suggesting these combinations are suitable as rescue therapy in highly treatment-experienced patients. from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008